Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy
NCT06568042Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of LY3848575 in neuropathic pain, distal sensory polyneuropathy (DSP), sponsored by Eli Lilly and Company. Started Aug 2024; status: completed.
02
Drugs
LY3848575
03
Conditions
neuropathic paindistal sensory polyneuropathy (DSP)
Beyond the preview
Go deeper on NCT06568042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568042.